Zobrazeno 1 - 10
of 52
pro vyhledávání: '"David Flyer"'
Autor:
Ying Liu, Ling Ye, Fang Lin, Yasmine Gomaa, David Flyer, Ricardo Carrion, Jean L. Patterson, Mark R. Prausnitz, Gale Smith, Gregory Glenn, Hua Wu, Richard W. Compans, Chinglai Yang
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/ff2b5d4e8873422293eb5e1c62295876
Autor:
Qingqing Xie, Zhao Wang, Fengyun Ni, Xiaorui Chen, Jianpeng Ma, Nita Patel, Hanxin Lu, Ye Liu, Jing-Hui Tian, David Flyer, Michael J Massare, Larry Ellingsworth, Gregory Glenn, Gale Smith, Qinghua Wang
Publikováno v:
PLoS ONE, Vol 14, Iss 2, p e0210749 (2019)
Globally, human respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in newborns, young children, and the elderly for which there is no vaccine. The RSV fusion (F) glycoprotein is a major target for vaccine devel
Externí odkaz:
https://doaj.org/article/cfdeb2d3629d4702a3334786e4caba93
Autor:
Sarah Katharina Fehling, Louis Fries, Jay W. Hooper, Stephan Becker, Judy Wen, Verena Krähling, Gale Smith, Gregory M. Glenn, David Flyer, Thomas Strecker, Sapeckshita Agrawal, Amy Fix, Steven A. Kwilas, Nigel Thomas, Maggie Lewis, Iksung Cho
Publikováno v:
The Journal of Infectious Diseases. 222:572-582
Background Ebola virus (EBOV) epidemics pose a major public health risk. There currently is no licensed human vaccine against EBOV. The safety and immunogenicity of a recombinant EBOV glycoprotein (GP) nanoparticle vaccine formulated with or without
Autor:
Gale Smith, Rama Raghunandan, Yingyun Wu, Ye Liu, Michael Massare, Margret Nathan, Bin Zhou, Hanxin Lu, Sarathi Boddapati, Jingning Li, David Flyer, Gregory Glenn
Publikováno v:
PLoS ONE, Vol 7, Iss 11, p e50852 (2012)
Respiratory Syncytial Virus (RSV) is an important viral agent causing severe respiratory tract disease in infants and children as well as in the elderly and immunocompromised individuals. The lack of a safe and effective RSV vaccine represents a majo
Externí odkaz:
https://doaj.org/article/0a7aca2c825048ba8fb18a9332825bee
Autor:
Ye Liu, Bin Zhou, Nita Patel, Gale Smith, Larry Ellingsworth, Michael J. Massare, Maggie Lewis, James F. Cummings, David Flyer, Greg Glenn
Publikováno v:
Vaccine. 35:5366-5372
Influenza viruses frequently acquire mutations undergoing antigenic drift necessitating annual evaluation of vaccine strains. Highly conserved epitopes have been identified in the hemagglutinin (HA) head and stem regions, however, current influenza v
Autor:
Bin Zhou, Larry Elllingsworth, Ye Liu, Gregory M. Glenn, Jing-Hui Tian, David Flyer, Gale Smith, Eddie Sullivan, Hua Wu, James F. Cummings
Publikováno v:
Vaccine. 35:4079-4087
Clostridium difficile is the number one cause of nosocomial antibiotic-associated diarrhea in developed countries. Historically, pathogenesis was attributed two homologous glucosylating toxins, toxin-A (TcdA) and toxin-B (TcdB). Over the past decade,
Autor:
Michael J. Massare, Gregory M. Glenn, David Flyer, Bin Zhou, Sapeckshita Agrawal, Gale Smith, Vivek Shinde, Michelle Spindler, Louis Fries, Timothy J. Hahn, Iksung Cho, Yukun Wu, D Nigel Thomas, Elizabeth Lindner, Amy Fix, Joyce S Plested
Publikováno v:
New England Journal of Medicine. 378:2346-2348
Improving the Influenza Vaccine Many approaches are being sought to improve the vaccine against influenza virus. In this report, data on the immunogenicity of a nanoparticle vaccine with a baculovi...
Autor:
Jing-Hui Tian, Michael J. Massare, Vadim A. Ivanov, Robert C. Welliver, Larry Ellingsworth, Gale Smith, Hanxin Lu, James F. Papin, Mimi Guebre-Xabier, David Flyer, Greg Glenn, Alisha Preno
Publikováno v:
Vaccine. 38(5)
Globally, human respiratory syncytial virus (RSV) is a major cause of severe lower respiratory infection in infants and young children. There are no licensed vaccines despite the high worldwide disease burden. RSV fusion (F) glycoprotein vaccine is t
Autor:
Xiaorui Chen, Jing-Hui Tian, Gale Smith, Jianpeng Ma, Ye Liu, Zhao Wang, Hanxin Lu, Fengyun Ni, Gregory M. Glenn, David Flyer, Nita Patel, Qinghua Wang, Qingqing Xie, Michael J. Massare, Larry Ellingsworth
Publikováno v:
PLoS ONE, Vol 14, Iss 2, p e0210749 (2019)
PLoS ONE
PLoS ONE
Globally, human respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in newborns, young children, and the elderly for which there is no vaccine. The RSV fusion (F) glycoprotein is a major target for vaccine devel
Autor:
David Flyer, Louis Fries, Eloi Kpamegan, Gregory M. Glenn, Somia P. Hickman, Mimi Guebre-Xabier, Gale Smith, Hanxin Lu
Publikováno v:
Vaccine. 33(47):6488-6492
Background Protection of newborns and young infants against RSV disease via maternal immunization mediated by transplacental transfer of antibodies is under evaluation in third-trimester pregnant women with the RSV recombinant F nanoparticle vaccine